A European Union approved the use of Kittyan innovative drug of the pharmacist Eli Lillyto treat patients with light cognitive impairment or light dementia nos Initial stages of Alzheimer’s.
Authorization was granted after a positive scientific evaluation by European Medicines Agency (EMA) and establishes rigorous criteria for the use of the drug, due to its potential risks.
Kisunla is based on the molecule donanemabwhich operates in the fight against the accumulation of beta-amyloid In the brain, one of the main characteristics of the disease of. By reducing these signs, the medicine seeks Delay the progression of cognitive and functional symptoms of the disease.
The main objective of treatment with Kisunla is provide a slowdown in the advancement of especially in the early stages, when it is still possible to preserve some of the patient’s autonomy and quality of life. However, This is not a curebut in a way to contain the advance of brain deterioration.
Kisunla’s approval does not mean that it will be widely distributed to all patients with Alzheimer’s. THE European Commission imposed strict conditions for its use.
The drug will be indicated for patients only in the early stages of the disease and that do not present a specific genetic mutation May they make them more susceptible to serious side effects.
Among the main reported adverse effectsthey are brain edema (swelling in the brain) e bleedingwhich, in rare cases, can be fatal. Therefore, European authorization requires risk mitigation measureshow strict monitoring of patients and clear labeling of the drug regarding its contraindications and possible complications.
Despite its innovative potential, Kisunla has been the target of debate between specialists. Some doctors and researchers celebrate the results of clinical trialswhich showed previously unpublished effects in combating the progression of the disease. After decades of frustrated attempts, this type of medicine represents a breakthrough.
On the other hand, there are those who question whether the clinical benefit obtained is really significant for patients in everyday life. According to critics, even if laboratory and statistical results show an improvement, Practical impact can be limited.
Kisunla follows the steps of This is the (Lecanemab), from Biogen and ESAI, another similar drug approved by the EU at the end of 2024, after being initially rejected. Like Leqmbi, Kisunla was First refused by EMAbut was eventually authorized under specific conditions after new analysis.
Both medicines represent a new generation of treatments that mark a Change in Alzheimer’s approach paradigmfocusing on early intervention and modulation of neurodegenerative processes before brain damage is irreversible.
